AbbVie: Income Anchor with Upside If Immunology Growth Continues
AbbVie combines a 3.2% yield, industry-leading free cash flow and a growing immunology franchise that replaced Humira. The stock is digesting gains and trading near technical support; a disciplined long trade with tight risk control offers asymmetric reward if Skyrizi/Rinvoq execution and margin recovery persist.